In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Meletios A Dimopoulos, A. Keith Stewart, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Veselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Sunhee Ro, Sanjay Aggarwal, Philippe Moreau, Antonio Palumbo
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczysław Komarnicki, Kenshi Suzuki, Torben Plesner, Sung‐Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau
Meletios A Dimopoulos, Jesús F. San Miguel, Andrew R. Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis,
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen,
Discussion(0)
No comments yet. Be the first to comment.